Suggested remit To appraise the clinical and cost effectiveness of lumasiran within its marketing authorisation for treating primary hyperoxaluria type 1.
Status Proposed
Process STA 2018
ID number 3765

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
24 July 2020 (14:00) Scoping workshop (Manchester)
05 June 2020 - 03 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance